Literature DB >> 15950325

Design, synthesis and in vitro and in vivo antitumor activities of novel beta-carboline derivatives.

R Cao1, H Chen, W Peng, Y Ma, X Hou, H Guan, X Liu, A Xu.   

Abstract

To further our SAR study on the chemistry and antitumor activity/neurotoxicity of beta-carboline alkaloids, several series of beta-carboline derivatives with various substituents were designed and synthesized from the starting material l-tryptophan on the basis of harmine chemical structure. Cytotoxic activities of these compounds were investigated in vitro. The results showed that some beta-carboline derivatives had significant cytotoxic activities against human tumor cell lines. Among all the synthesized beta-carboline derivatives, the compounds 27, 28 and 32, having a benzyl substituent at both position-2 and 9, respectively, were found to be the most potent compounds with IC50 value lower than 50 microM against all human tumor cell lines examined. Acute toxicities and antitumor activities of the selected beta-carboline derivatives in mice were also evaluated. The results demonstrated that a benzyl substituent at position-2 increased the antitumor activity as well as acute toxicity significantly. However an (ethoxycarbonyl)amino substituent at position-3 reduced the acute toxicity as well as antitumor activity remarkedly. These data suggested that (1) the antitumor potencies of beta-carboline derivatives were enhanced by the introduction of benzyl substituent into the position-2; (2) the acute toxicity of beta-carboline derivatives reduced dramatically by the introduction of an appropriate substituent into the position-3 and 9; (3) the beta-carboline structure might be an important basis for the design and synthesis of new antitumor drugs with significant antitumor activity and low toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950325     DOI: 10.1016/j.ejmech.2005.04.008

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol.

Authors:  Mohamed A M El Gendy; Anatoly A Soshilov; Michael S Denison; Ayman O S El-Kadi
Journal:  Toxicol Lett       Date:  2011-10-06       Impact factor: 4.372

2.  Mitochondrial Dysfunction Induced by N-Butyl-1-(4-Dimethylamino)Phenyl-1,2,3,4-Tetrahydro-β-Carboline-3-Carboxamide Is Required for Cell Death of Trypanosoma cruzi.

Authors:  Hélito Volpato; Vânia Cristina Desoti; Rodrigo Hinojosa Valdez; Tânia Ueda-Nakamura; Sueli de Oliveira Silva; Maria Helena Sarragiotto; Celso Vataru Nakamura
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

3.  Synthesis and In Vitro Antitumor Activity of Novel Bivalent β-Carboline-3-carboxylic Acid Derivatives with DNA as a Potential Target.

Authors:  Hongling Gu; Na Li; Jiangkun Dai; Yaxi Xi; Shijun Wang; Junru Wang
Journal:  Int J Mol Sci       Date:  2018-10-15       Impact factor: 5.923

4.  Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents.

Authors:  Xiaofei Chen; Liang Guo; Qin Ma; Wei Chen; Wenxi Fan; Jie Zhang
Journal:  Molecules       Date:  2019-08-14       Impact factor: 4.411

5.  Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity.

Authors:  Maja Beus; Leentje Persoons; Dirk Daelemans; Dominique Schols; Kirsi Savijoki; Pekka Varmanen; Jari Yli-Kauhaluoma; Kristina Pavić; Branka Zorc
Journal:  Mol Divers       Date:  2022-01-08       Impact factor: 3.364

Review 6.  β-Carboline-based molecular hybrids as anticancer agents: a brief sketch.

Authors:  Jay Prakash Soni; Yogesh Yeole; Nagula Shankaraiah
Journal:  RSC Med Chem       Date:  2021-03-24

7.  The Effects of N-Butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro- β -carboline-3-carboxamide against Leishmania amazonensis Are Mediated by Mitochondrial Dysfunction.

Authors:  Hélito Volpato; Vânia Cristina Desoti; Juliana Cogo; Manuela Ribeiro Panice; Maria Helena Sarragiotto; Sueli de Oliveira Silva; Tânia Ueda-Nakamura; Celso Vataru Nakamura
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-13       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.